ArticleCancer immunology, immunotherapy : CII2024

Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.

Panpan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.